Breakthrough cancer therapy

My research team have made a big contribution to answering why cancers are so difficult to cure.

We would like to inform you of a recent breakthrough in our cancer studies at the Griffith University Health Research Institute that will greatly improve cancer treatment. Our results are truly remarkable and scientifically amazing and have just been published online in the Springer medical journal: Angiogenesis.

We have shown that cancer cells secrete a protein (Galectin-1) in high levels that protects cancers, like a shield or shell around them. This protein promotes the blood supply to cancers as well as killing any immune cells before they have a chance to attack the cancer.

By using a drug design based on a sugar molecule, we can now block the action of this protein with the result that the growth of breast cancers and skin cancers in animals was very much slowed down.

We have shown that the sugar based drug works by blocking the shield, allowing immune killer cells to then enter into the tumours so that they are able to attack and kill the cancer cells. Our drug also disrupts the blood supply to cancers. This treatment has been shown in animal models of cancer to greatly increase the potency of cancer therapies and cancer vaccines.

This novel treatment has not shown any side effects in animals given very high levels and is likely to have huge benefits for making anticancer vaccines much stronger.

It should also help make other immune based cancer treatments more effective when combined with our drug. With the recent FDA approved Yervoy therapy, we expect that human clinical trials will show similar findings with our drug, heralding a new way to treat cancer as we know it. The attached file shows a video animation describing how our treatment works.

Sincerely,




Associate Professor Steve Ralph




School of Medical Science
Griffith University
Parklands
Gold Coast campus
Southport
Australia

Category:

Science & Technology

Tags:

• BREAKTHROUGH
• CANCER
• THERAPY
• medicine

[DrSTEVERALPH]

TDG has not been tested in clincal trials yet and is not approved as such for use in humans. It has only been tested in animal studies for cancer so far, but is aimed to start clinical trials in late 2011.

[smartguy6914]

What is the non-digestive sugar called? Would be important to me. Has is anything to do with Isopropyl β-D-1-thiogalactopyranoside or thiogalactoside? I could only recently derive the a.m. names acoustically from a tv-report.

Any further information is appreciated!

[DrSTEVERALPH]

@smartguy6914

The drug is the second disaccharide, abbreviated TDG for thiodigalactoside. All the information we have at present is published and freely available. You can download the online article at the SpringerLink - Angiogenesis journal site.

TITLE:

Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress.

AUTHORS: Ito K, et al. Angiogenesis. 2011 Apr 27.

[figbat1]

want to know something really special that the griffith university school of medical science and ASIO (aka the mickey mouse club) and the australian government dont want anyone to know.............go to "out of mind out of sight the models nzoz1985" and press "see all" to find my 3 comments.

[Herbhip]

What was the Result of the Clinical Trials? Has/is TDG treatment been approved for the market?